Next-generation dendritic cell vaccines

Vaccine makers have known for years that delivering immunogenic antigens to dendritic cells can elicit the strong T cell-based immune response that is key to combating viral and bacterial infections and cancer. But complexities of vaccine formulation and dosing have made delivering the antigens todendritic cells in vivo a challenge.

Now, American researchers have devised two methods to maximize the uptake and presentation of antigens by dendritic cells (DCs) and have demonstrated potent cellular immunity in mice and monkeys vaccinated using the techniques...